Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 10 | 2023 | 2428 | 0.760 |
Why?
|
| Atherosclerosis | 6 | 2025 | 1002 | 0.570 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 2090 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 343 | 0.490 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2023 | 382 | 0.390 |
Why?
|
| Echocardiography | 4 | 2023 | 1131 | 0.310 |
Why?
|
| Cardiology | 2 | 2024 | 521 | 0.290 |
Why?
|
| Hypertension | 3 | 2024 | 1396 | 0.280 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 191 | 0.280 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 695 | 0.260 |
Why?
|
| Heart Diseases | 2 | 2024 | 526 | 0.260 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 6 | 0.240 |
Why?
|
| Apolipoprotein C-III | 1 | 2025 | 46 | 0.230 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2005 | 54 | 0.230 |
Why?
|
| NF-kappa B | 3 | 2003 | 482 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2018 | 422 | 0.220 |
Why?
|
| Hypertriglyceridemia | 1 | 2025 | 114 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 257 | 0.210 |
Why?
|
| Cardiologists | 1 | 2023 | 24 | 0.210 |
Why?
|
| Hypolipidemic Agents | 1 | 2025 | 190 | 0.210 |
Why?
|
| Income | 1 | 2024 | 140 | 0.210 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 148 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2024 | 110 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2015 | 80 | 0.200 |
Why?
|
| Triglycerides | 1 | 2025 | 617 | 0.190 |
Why?
|
| Cause of Death | 1 | 2024 | 507 | 0.190 |
Why?
|
| United States | 11 | 2024 | 11748 | 0.190 |
Why?
|
| Aortic Valve | 1 | 2005 | 469 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 409 | 0.180 |
Why?
|
| Warfarin | 1 | 2022 | 125 | 0.180 |
Why?
|
| Hospitalization | 3 | 2024 | 1901 | 0.180 |
Why?
|
| Humans | 35 | 2025 | 134064 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1157 | 0.170 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.160 |
Why?
|
| Adult | 15 | 2025 | 31961 | 0.160 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 676 | 0.150 |
Why?
|
| Trypanosoma cruzi | 1 | 2021 | 251 | 0.140 |
Why?
|
| Thrombosis | 1 | 2022 | 547 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2021 | 309 | 0.140 |
Why?
|
| Middle Aged | 12 | 2025 | 29399 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 638 | 0.130 |
Why?
|
| Apoptosis | 1 | 2003 | 1944 | 0.130 |
Why?
|
| Cocaine | 1 | 2018 | 208 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 252 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 518 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 480 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1102 | 0.120 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 5 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 239 | 0.120 |
Why?
|
| Postprandial Period | 1 | 2015 | 91 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 38 | 0.120 |
Why?
|
| Male | 17 | 2025 | 66047 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 469 | 0.110 |
Why?
|
| Carotid Arteries | 1 | 2015 | 151 | 0.110 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 72 | 0.110 |
Why?
|
| Female | 18 | 2025 | 71846 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2018 | 834 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 894 | 0.110 |
Why?
|
| Risk Factors | 6 | 2025 | 11164 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 807 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 198 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2015 | 300 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2019 | 1062 | 0.090 |
Why?
|
| Age of Onset | 2 | 2025 | 637 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 69 | 0.090 |
Why?
|
| American Heart Association | 2 | 2024 | 329 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2771 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 140 | 0.090 |
Why?
|
| Prevalence | 3 | 2024 | 2684 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 545 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 535 | 0.080 |
Why?
|
| Inpatients | 2 | 2024 | 542 | 0.080 |
Why?
|
| Aged | 6 | 2024 | 21753 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 433 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 497 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 285 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2021 | 365 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 60 | 0.070 |
Why?
|
| Texas | 3 | 2024 | 3715 | 0.070 |
Why?
|
| Prognosis | 3 | 2025 | 5084 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17517 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 149 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 9916 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 772 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2024 | 73 | 0.060 |
Why?
|
| Chest Pain | 1 | 2005 | 133 | 0.060 |
Why?
|
| Dyspnea | 1 | 2005 | 160 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 104 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 35 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2003 | 39 | 0.050 |
Why?
|
| Age Factors | 2 | 2025 | 2997 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 42 | 0.050 |
Why?
|
| Ligation | 1 | 2003 | 137 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 319 | 0.050 |
Why?
|
| Heart Ventricles | 3 | 2022 | 804 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 937 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2025 | 3729 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 53 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1416 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 38 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 51 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 262 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2024 | 246 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 114 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2264 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 231 | 0.050 |
Why?
|
| Animals | 7 | 2025 | 36539 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 293 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 259 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1340 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 7205 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2002 | 156 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 249 | 0.040 |
Why?
|
| Insect Vectors | 1 | 2021 | 114 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2002 | 198 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 299 | 0.040 |
Why?
|
| Echocardiography, Stress | 1 | 2020 | 18 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 225 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2003 | 567 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 1094 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2218 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1625 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 110 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 574 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2002 | 417 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 206 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1250 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 1420 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1095 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 12 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 32 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1255 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 464 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 2538 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 130 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1195 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2018 | 76 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 614 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 127 | 0.030 |
Why?
|
| Heart | 1 | 2002 | 749 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1387 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3414 | 0.030 |
Why?
|
| Ischemia | 1 | 2020 | 384 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2002 | 1027 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 6604 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 20600 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 680 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 703 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2015 | 1004 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 3043 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 51 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 13049 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 153 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 757 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 565 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 80 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3753 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2002 | 93 | 0.020 |
Why?
|
| Cyclic GMP | 2 | 2002 | 105 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 2 | 2002 | 177 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2002 | 146 | 0.020 |
Why?
|
| Toll-Like Receptors | 2 | 2002 | 85 | 0.020 |
Why?
|
| Mice | 3 | 2003 | 19042 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 115 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1492 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1155 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2002 | 914 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3999 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 129 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2002 | 872 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2170 | 0.020 |
Why?
|
| Myocardium | 2 | 2002 | 1046 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1736 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 79 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 123 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 103 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 153 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 57 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 184 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2002 | 174 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 371 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 173 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 145 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 124 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 303 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2196 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 837 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 689 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2002 | 667 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2793 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 932 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3979 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 1400 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1761 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2911 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 1593 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 4012 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4877 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 4933 | 0.000 |
Why?
|